Efficacy and Safety of Increasing Doses of DaxibotulinumtoxinA for Injection (DAXI for Injection) in the Treatment of Moderate or Severe Lateral Canthal Lines
Clinical trial NCT03911102 · COMPLETED
Trial details
- NCT number
- NCT03911102
- Sponsor
- Revance Therapeutics, Inc.
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2019-03-11
- Primary completion
- 2020-04-23
- Enrollment
- 63
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.